- Home
- FTHM vs SCYX Comparison
FTHM vs SCYX Comparison
Compare FTHM & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTHM | SCYX |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1M | 32.6M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | FTHM | SCYX |
|---|---|---|
| Price | $1.00 | $0.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.50 | ★ $3.00 |
| AVG Volume (30 Days) | 102.1K | ★ 332.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $335,184,000.00 | $257,000.00 |
| Revenue This Year | $30.07 | $170.77 |
| Revenue Next Year | $14.66 | $286.38 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.65 | $0.57 |
| 52 Week High | $3.37 | $1.29 |
Technical Indicators
Market Signals| Indicator | FTHM | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 45.35 | 49.03 |
| Support Level | $0.90 | $0.69 |
| Resistance Level | $1.50 | $0.88 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 34.52 | 26.71 |
Price Performance
Historical ComparisonAbout FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.